Kura Oncology, Inc. $KURA Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC trimmed its position in Kura Oncology, Inc. (NASDAQ:KURA) by 13.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,582,568 shares of the company’s stock after selling 247,998 shares during the period. Renaissance Technologies LLC’s holdings in Kura Oncology were worth $12,866,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Kura Oncology by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after acquiring an additional 2,977 shares in the last quarter. Strs Ohio purchased a new stake in shares of Kura Oncology during the first quarter worth approximately $143,000. Legal & General Group Plc increased its position in shares of Kura Oncology by 35.1% during the second quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock worth $421,000 after purchasing an additional 18,930 shares in the last quarter. Rhumbline Advisers increased its position in shares of Kura Oncology by 13.0% during the second quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock worth $686,000 after purchasing an additional 13,690 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in Kura Oncology by 244.5% in the 2nd quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock valued at $1,343,000 after purchasing an additional 165,189 shares during the last quarter.

Kura Oncology Price Performance

KURA stock opened at $9.01 on Friday. Kura Oncology, Inc. has a 1 year low of $5.45 and a 1 year high of $12.49. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. The firm has a market capitalization of $799.82 million, a PE ratio of -2.69 and a beta of 0.35. The business has a 50 day simple moving average of $10.19 and a 200-day simple moving average of $9.27.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million for the quarter, compared to the consensus estimate of $25.97 million. Equities research analysts anticipate that Kura Oncology, Inc. will post -3.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KURA has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Wall Street Zen raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Oppenheimer set a $24.00 target price on shares of Kura Oncology in a research report on Thursday, May 28th. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Finally, Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a research report on Monday, June 15th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.46.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the sale, the insider directly owned 182,345 shares in the company, valued at $1,790,627.90. This represents a 31.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 7.60% of the stock is currently owned by insiders.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.